NOVAVAX INC (NVAX)
NOVAVAX INC (NVAX) from its SEC filings: 2025 revenue $1.1 billion (+65% vs the year before), net margin 39%, free cash flow -$244.6 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $1.1 billion |
| Revenue growth | +65% |
| Net income | $440.3 million |
| Net margin | 39.2% |
| Free cash flow | -$244.6 million |
| Diluted EPS | $2.58 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -76% |
| Cash | $191.5 million |
| Long-term debt | $291.5 million |
| Share count, 1 year | +2% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.